Coronado Biosciences Announces Key Addition to Management Team
January 02, 2013 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Acquires TSO Manufacturing Rights From Ovamed
December 27, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Announces Phase 2 Study Evaluating TSO in Ulcerative Colitis
December 21, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at the Oppenheimer 23rd Annual Healthcare Conference
December 05, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Initiates Phase 1/2 Trial of CNDO-109 Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia
November 28, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
November 21, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 21, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2012
November 14, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Autism Spectrum Disorders
November 12, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Report Third Quarter 2012 Financial Results
November 07, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
November 06, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...